Skip to main content

Entyvio News

U.S. FDA Approves Subcutaneous Administration of Takeda’s Entyvio (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

OSAKA, Japan April 19, 2024 and CAMBRIDGE, Massachusetts, April 18, 2024 – Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved Entyvio® (v...

U.S. FDA Approves Subcutaneous Administration of Takeda's Entyvio (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

OSAKA, Japan and CAMBRIDGE, Massachusetts, September 27, 2023 – Takeda today announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) administration of Entyvio® (v...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Crohn's Disease - Maintenance, Ulcerative Colitis, Crohn's Disease

Entyvio patient information at Drugs.com